

# Norman T Ilowite

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6366817/publications.pdf>

Version: 2024-02-01

65  
papers

7,802  
citations

81743

39  
h-index

118652

62  
g-index

69  
all docs

69  
docs citations

69  
times ranked

4789  
citing authors

#	ARTICLE	IF	CITATIONS
1	Etanercept in Children with Polyarticular Juvenile Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2000, 342, 763-769.	13.9	1,125
2	2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. <i>Arthritis Care and Research</i> , 2011, 63, 465-482.	1.5	658
3	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2016, 68, 566-576.	2.9	427
4	Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: Report of forty-six patients from an international multicenter series. <i>Arthritis and Rheumatism</i> , 2011, 63, 545-555.	6.7	397
5	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 481-489.	0.5	338
6	Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus. <i>Journal of Rheumatology</i> , 2019, 46, 190-197.	1.0	318
7	The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor $\beta$ -chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2007, 56, 965-971.	6.7	294
8	Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2008, 58, 1496-1504.	6.7	285
9	Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2012, 64, 2012-2021.	6.7	259
10	Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: Interim results from an ongoing multicenter, open-label, extended-treatment trial. <i>Arthritis and Rheumatism</i> , 2003, 48, 218-226.	6.7	228
11	Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. <i>Arthritis and Rheumatism</i> , 2007, 56, 3793-3804.	6.7	216
12	2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among Children Receiving Biologic Medications. <i>Arthritis and Rheumatism</i> , 2013, 65, 2499-2512.	6.7	211
13	2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among Children Receiving Biologic Medications. <i>Arthritis Care and Research</i> , 2013, 65, 1551-1563.	1.5	211
14	Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. <i>Arthritis Care and Research</i> , 2012, 64, 1001-1010.	1.5	172
15	Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2006, 54, 1987-1994.	6.7	166
16	Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2009, 60, 2102-2112.	6.7	153
17	<i>HLA-DRB1*11</i> and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 15970-15975.	3.3	139
18	Development of consensus treatment plans for juvenile localized scleroderma: A roadmap toward comparative effectiveness studies in juvenile localized scleroderma. <i>Arthritis Care and Research</i> , 2012, 64, 1175-1185.	1.5	137

#	ARTICLE	IF	CITATIONS
19	Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2014, 66, 2570-2579.	2.9	130
20	Premature atherosclerosis in pediatric systemic lupus erythematosus: Risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort. <i>Arthritis and Rheumatism</i> , 2009, 60, 1496-1507.	6.7	125
21	Current Treatment of Juvenile Rheumatoid Arthritis. <i>Pediatrics</i> , 2002, 109, 109-115.	1.0	124
22	Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 906-913.	0.5	123
23	Prevalence of and annual ambulatory health care visits for pediatric arthritis and other rheumatologic conditions in the United States in 2001-2004. <i>Arthritis and Rheumatism</i> , 2007, 57, 1439-1445.	6.7	106
24	Juvenile Idiopathic Arthritis. <i>Pediatric Clinics of North America</i> , 2005, 52, 413-442.	0.9	103
25	Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab. <i>Arthritis and Rheumatology</i> , 2016, 68, 218-228.	2.9	103
26	Consensus treatments for moderate juvenile dermatomyositis: Beyond the first two months. Results of the Second Childhood Arthritis and Rheumatology Research Alliance Consensus Conference. <i>Arthritis Care and Research</i> , 2012, 64, 546-553.	1.5	101
27	Performance of Current Guidelines for Diagnosis of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2014, 66, 2871-2880.	2.9	101
28	The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12 months. <i>Pediatric Rheumatology</i> , 2017, 15, 30.	0.9	80
29	Comparison of the intraarticular effectiveness of triamcinolone hexacetonide and triamcinolone acetonide in treatment of juvenile rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2004, 31, 2507-12.	1.0	71
30	Detection of Active Disease in Juvenile Idiopathic Arthritis: Sensitivity and Specificity of the Physical Examination vs Ultrasound. <i>Journal of Rheumatology</i> , 2011, 38, 2671-2674.	1.0	68
31	Gene expression signatures in polyarticular juvenile idiopathic arthritis demonstrate disease heterogeneity and offer a molecular classification of disease subsets. <i>Arthritis and Rheumatism</i> , 2009, 60, 2113-2123.	6.7	66
32	An i2b2-based, generalizable, open source, self-scaling chronic disease registry. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2013, 20, 172-179.	2.2	66
33	Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 557-566.	0.5	65
34	Clinically Inactive Disease in a Cohort of Children with New-onset Polyarticular Juvenile Idiopathic Arthritis Treated with Early Aggressive Therapy: Time to Achievement, Total Duration, and Predictors. <i>Journal of Rheumatology</i> , 2014, 41, 1163-1170.	1.0	61
35	Juvenile Idiopathic Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2007, 33, 441-470.	0.8	57
36	Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. <i>RMD Open</i> , 2016, 2, e000161.	1.8	57

#	ARTICLE	IF	CITATIONS
37	Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2010, 62, 3259-3264.	6.7	54
38	Measuring process of arthritis care: A proposed set of quality measures for the process of care in juvenile idiopathic arthritis. <i>Arthritis Care and Research</i> , 2011, 63, 10-16.	1.5	53
39	Update on biologics in juvenile idiopathic arthritis. <i>Current Opinion in Rheumatology</i> , 2008, 20, 613-618.	2.0	45
40	<i>IL1RN</i> Variation Influences Both Disease Susceptibility and Response to Recombinant Human Interleukin-1 Receptor Antagonist Therapy in Systemic Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 1319-1330.	2.9	40
41	Panniculitis and fever in children. <i>Journal of Pediatrics</i> , 1993, 122, 372-378.	0.9	31
42	PHARMACOLOGY AND DRUG THERAPY. , 2011, , 71-126.		26
43	Using Registries to Identify Adverse Events in Rheumatic Diseases. <i>Pediatrics</i> , 2013, 132, e1384-e1394.	1.0	25
44	Panniculitis, infection, and dermatomyositis: case and literature review. <i>Clinical Rheumatology</i> , 2009, 28, 57-63.	1.0	22
45	Canakinumab for the treatment of active systemic juvenile idiopathic arthritis. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 1015-1024.	1.3	22
46	Algorithm development for corticosteroid management in systemic juvenile idiopathic arthritis trial using consensus methodology. <i>Pediatric Rheumatology</i> , 2012, 10, 31.	0.9	19
47	Systemic Lupus Erythematosus in Children and Adolescents. <i>Pediatrics in Review</i> , 2006, 27, 323-330.	0.2	17
48	Giant coronary artery aneurysms in juvenile polyarteritis nodosa: a case report. <i>Pediatric Rheumatology</i> , 2012, 10, 1.	0.9	16
49	Panniculitis and lipodystrophy. <i>Current Opinion in Rheumatology</i> , 2002, 14, 566-570.	2.0	13
50	A Dose Schedule for Intraarticular Steroids in Juvenile Arthritis: Table 1.. <i>Journal of Rheumatology</i> , 2012, 39, 374-376.	1.0	10
51	Cranial Nerve Involvement With Juvenile Polyarteritis Nodosa: Clinical Manifestations and Treatment. <i>Pediatrics</i> , 2010, 126, e719-e722.	1.0	9
52	Treatment of rheumatic diseases in children: special considerations. <i>Rheumatic Disease Clinics of North America</i> , 2002, 28, 461-482.	0.8	8
53	Juvenile idiopathic arthritis: an update on current pharmacotherapy and future perspectives. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 975-989.	0.9	8
54	Systemic Juvenile Idiopathic Arthritis: A Review. <i>Pediatric Annals</i> , 2012, 41, .	0.3	6

#	ARTICLE	IF	CITATIONS
55	Interleukin-1 in monocyte activation phenotypes in systemic juvenile idiopathic arthritis: Observations from a clinical trial of riloncept, an interleukin-1 inhibitor. <i>Clinical Immunology</i> , 2018, 194, 9-18.	1.4	6
56	Chronic Leg Ulceration as the Presenting Feature of Diffuse Systemic Sclerosis in Childhood. <i>Journal of Pediatrics</i> , 2011, 159, 698.	0.9	5
57	Prevalence of Annexin A5 Resistance in Children and Adolescents with Rheumatic Diseases. <i>Journal of Rheumatology</i> , 2012, 39, 382-388.	1.0	4
58	Novel treatment options for juvenile idiopathic arthritis. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 559-573.	1.3	4
59	Wasabi nose: an underreported complication of cyclophosphamide infusions. <i>Clinical Rheumatology</i> , 2011, 30, 1003-1005.	1.0	3
60	Vaccination in pediatric rheumatic disease—risks and benefits. <i>Nature Reviews Rheumatology</i> , 2012, 8, 188-190.	3.5	3
61	Systemic Lupus Erythematosus in Children and Adolescents. <i>Pediatrics in Review</i> , 2006, 27, 323-330.	0.2	3
62	Ultrasound and Cartilage Thickness in Juvenile Idiopathic Arthritis: New Findings, New Questions. <i>Journal of Rheumatology</i> , 2013, 40, 1466-1468.	1.0	1
63	Reply. <i>Arthritis and Rheumatology</i> , 2015, 67, 858-858.	2.9	1
64	Management of the Connective Tissue Diseases of Childhood. , 2010, , 249-274.		0
65	A167: Variations in Patterns of Care Across Pediatric Rheumatic Diseases in the Childhood Arthritis & Rheumatology Alliance Network Registry. <i>Arthritis and Rheumatology</i> , 2014, 66, S215-S216.	2.9	0